KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Acquisitions & Divestments (2018 - 2025)

Historic Change in Acquisitions & Divestments for Arbutus Biopharma (ABUS) over the last 10 years, with Q3 2025 value amounting to $41.3 million.

  • Arbutus Biopharma's Change in Acquisitions & Divestments rose 4561.2% to $41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.1 million, marking a year-over-year increase of 2201.04%. This contributed to the annual value of $164.6 million for FY2024, which is 2447.19% up from last year.
  • Arbutus Biopharma's Change in Acquisitions & Divestments amounted to $41.3 million in Q3 2025, which was up 4561.2% from $44.1 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Change in Acquisitions & Divestments peaked at $56.7 million during Q4 2024, and registered a low of $2.0 million during Q1 2022.
  • In the last 5 years, Arbutus Biopharma's Change in Acquisitions & Divestments had a median value of $28.4 million in 2024 and averaged $29.2 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first crashed by 9017.2% in 2022, then soared by 175000.0% in 2023.
  • Over the past 5 years, Arbutus Biopharma's Change in Acquisitions & Divestments (Quarter) stood at $20.0 million in 2021, then rose by 30.0% to $26.0 million in 2022, then surged by 77.86% to $46.2 million in 2023, then grew by 22.58% to $56.7 million in 2024, then fell by 27.18% to $41.3 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $41.3 million for Q3 2025, versus $44.1 million for Q2 2025 and $46.1 million for Q1 2025.